Gene Editing Market Recent Developments and Future Trends
According to research report the Gene Editing Market is projected to reach USD 6.28 billion by 2022 from USD 3.19 billion in 2017, at a CAGR of 14.5% during the forecast period.
Ask For PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
The
market growth is largely driven by factors such as the rise in
government funding, growth in the number of genomics projects, high
prevalence of infectious diseases and cancer, technological
advancements, increasing production of genetically modified crops, and
growing application areas of genomics. However, the high cost of genomic
equipment will restrain the growth of this market.
Based on
application, the genome editing/genome engineering market is segmented
into cell line engineering, genetic engineering, diagnostic
applications, drug discovery & development, and other applications. A
number of factors, such as the increased funding from governments and
private organizations, growing industry focus on stem cell research, and
global awareness are driving market growth in this segment.
Pharmaceutical
companies accounted for the largest share of the Gene Editing Market,
by end user, in 2019. The increasing prevalence of infectious diseases
and cancer are driving research activities worldwide. This, in turn, is
expected to drive the demand for genome editing in pharmaceutical
companies.
The CRISPR technology segment accounted for the
largest share of the genome editing/genome engineering industry in 2019.
The large share of this segment can be attributed to the ease of use
associated with CRISPR, which gives it a significant advantage over ZFN
and TALEN. Another potential advantage is its ability to multiplex.
The
major companies in the Genome Engineering Genome Editing Market include
Thermo Fisher Scientific (US), Merck (Germany), Horizon Discovery
Limited (UK), Lonza (Switzerland), GenScript (US), Eurofins Scientific
(Luxembourg), and Sangamo Therapeutics (US).
Recent Developments:
>
In 2020, New England Biolabs collaborated with ERS Genomics to develop
and commercialize CRISPR gene editing tools and reagents
> In
2019, Thermo Fisher Scientific acquired Brammer Bio to access Brammer
Bio’s expertise in manufacturing vectors for genes and cell therapies
>
In 2019, Horizon Discovery launched predesigned synthetic single-guide
RNA (sgRNA) to aid researchers in achieving targeted gene knockouts and
conducting DNA-gene free editing
Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
The
Gene Editing Market is divided into four major regions—North America,
Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North
America accounted for the largest share of the global genome
editing/genome engineering market, closely followed by Europe. The large
share of North America can be attributed to factors such as the
development of gene therapy in the US, the increasing use of genetically
modified crops, the rising prevalence of infectious diseases and
cancer, and the availability of research grants and funding.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com
Comments
Post a Comment